24 August 2021 - Minjuvi is a new therapeutic option for eligible patients with DLBCL in Canada to address an urgent unmet medical need.
MorphoSys today announced that Health Canada has granted Incyte, its development and commercialization partner for tafasitamab, a Notice of Compliance with conditions for Minjuvi (tafasitamab), a humanised Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant.